Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 2010;201(5):720-9 doi: 10.1086/650492
Scientific Publications
- PMID: 20132004
- Title: Viral inhibition assay a CD8 T cell neutralization assay for use in clinical trials of HIV 1 vaccine candidates
- Abstract: We have characterized an assay measuring CD8 T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of primary HIV-1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay, avoids generation of T cell clones, and can be performed with 2 million peripheral blood mononuclear cells. Efficient CD8 T cell-mediated cross-clade inhibition of HIV-1 replication in vitro was demonstrated in antiretroviral therapy-naive HIV-1-infected subjects with controlled viral replication in vivo but not in viremic subjects. An HIV-1 vaccine candidate, consisting of DNA and recombinant adenovirus 5 vectors tested in a phase I clinical trial, induced CD8 T cells that efficiently inhibited HIV-1 in a HLA-I-dependent manner. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials.
- Date: 1970-08-20
- Year: 2010
- Journal: J. Infect. Dis.
- PMID Author: Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P
- IAVI Topics: HIV Epidemiology
- IAVI Keywords: HT Study
Viral inhibition assay a CD8 T cell neutralization assay for use in clinical trials of HIV 1 vaccine candidates
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
